Skip to main content
. 2017 Mar 28;8(26):42588–42601. doi: 10.18632/oncotarget.16585

Figure 6. GALNT6-enhanced behaviors are inhibited by EGFR inhibitor.

Figure 6

(A) GALNT6-increased phosphorylation of EGFR was inhibited by erlotinib in SKOV3 cells. (B) Transwell migration assays were performed to analyze effects of 5 μM erlotinib on cell migration in mock and GALNT6-overexpressed SKOV3 cells (mock + Erlotinib versus GALNT6 + Erlotinib, p=0.09). (C) Matrigel invasion assays were performed to analyze effects of erlotinib on cell invasion in mock and GALNT6-overexpressed SKOV3 cells (mock + Erlotinib versus GALNT6 + Erlotinib, p=0.44). Data are presented as mean ± SD from 3 independent experiments. (*p < 0.05; **p < 0.005).